This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Verastem Reports Data On Focal Adhesion Kinase Program At The 2012 EORTC Symposium On Molecular Targets And Cancer Therapeutics

Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported new data from its focal adhesion kinase (FAK) inhibition program and commented on encouraging clinical data on FAK inhibition presented at the 2012 EORTC Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland.

Data presented by Verastem in breast cancer models lacking the tumor suppressor Merlin demonstrate that FAK inhibition effectively reduces cancer stem cells in vitro and in vivo. Oral administration of a FAK inhibitor as a single agent was shown to induce tumor regression in a Merlin-negative breast cancer mouse model. These data extend previous research from Verastem, which demonstrated similar inhibition of cancer stem cells and strong single agent efficacy in Merlin-negative mesothelioma models.

Several groups presented data at the conference on the use of FAK inhibitors for treatment of cancer. In one clinical study by GlaxoSmithKline, researchers demonstrated that Merlin loss may identify a subset of patients with improved progression free survival in response to FAK inhibition. “These results provide important clinical validation of our internal research demonstrating enhanced sensitivity of Merlin-negative mesothelioma to FAK inhibitors,” said Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research.

Verastem anticipates initiating a potentially pivotal study in mesothelioma midyear 2013.

“The sum of the data on development of FAK inhibitors presented at this conference is very promising,” said Professor Dean Fennell, Chair of Thoracic Medical Oncology, University of Leicester. “In particular, GSK reported in a Phase 1 trial novel activity of a FAK inhibitor in mesothelioma, where treatment in the second and third-line setting resulted in a median progression free survival of 17.7 weeks.”

The largest clinical trial to date in malignant pleural mesothelioma was a 2011 Phase 3 study of Zolinza ® as a second- and third-line treatment conducted by Merck in 660 patients. In this study, a median progression free survival of only 6 weeks was observed.

“Interestingly, loss of the tumor suppressor Merlin correlated with increased clinical sensitivity to FAK inhibition,” Prof. Fennell continued. “A subset of patients with Merlin negative mesothelioma had more than double the median progression free survival of 24.1 weeks versus 11.4 weeks for the Merlin positive group. These early results suggest that a targeted therapy, particularly when used in combination with a specific biomarker, has the potential to significantly improve treatment of this aggressive and deadly disease.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs